Aktiebolaget Hassle v Alphapharm Pty Ltd

Link copied
Case Copied 72 min read

HIGH COURT OF AUSTRALIA

GLEESON CJ,
GAUDRON, McHUGH, GUMMOW, KIRBY, HAYNE AND CALLINAN JJ

AKTIEBOLAGET HÄSSLE & ANOR  APPELLANTS

AND

ALPHAPHARM PTY LIMITED   RESPONDENT

Aktiebolaget Hässle v Alphapharm Pty Limited [2002] HCA 59

12 December 2002
S287/2001

ORDER

1.   Appeal allowed with costs.

2.   Set aside orders made by the Full Court of the Federal Court on 9 October 2000.

3.   Matter remitted to the Full Court for the determination of any remaining grounds on the respondent's Notice of Contention.

4.   Order 2 made by Lehane J on 18 June 1999 dealing with revocation further stayed until further order of the Federal Court.

5.   Costs of the whole of the proceedings in the Federal Court to be in the discretion of the Full Court.

On appeal from the Federal Court of Australia

Representation:

J McL Emmerson QC with D M Yates SC and K J Howard for the appellants (instructed by Minter Ellison)

A C Bennett SC with S C G Burley and C Dimitriadis for the respondent (instructed by Mallesons Stephen Jaques)

Notice:  This copy of the Court's Reasons for Judgment is subject to formal revision prior to publication in the Commonwealth Law Reports.

  1. GLEESON CJ, GAUDRON, GUMMOW AND HAYNE JJ.   The appellants appeal from a decision of the Full Court of the Federal Court[1].  They are members of the Astra pharmaceutical group which is based in Sweden.  The first appellant is the patentee of Australian Standard Patent No 601,974 for an invention entitled "New Pharmaceutical Preparation for Oral Use" ("the Patent").  At the time of the grant, the Patents Act 1952 (Cth) ("the 1952 Act") was in force. The term of the Patent is for 20 years from 23 April 1987. The claimed priority date, apparently pursuant to s 141 of the 1952 Act, is 30 April 1986. This was the date of the basic application in the United Kingdom and the Australian application was made on 23 April 1987, that is to say, within the 12 months of the basic application as required by s 141. The second appellant is an Australian subsidiary of the Astra group and is the exclusive licensee of the Patent. It is convenient to refer to the appellants without distinction as "Astra".

    The Patent

  2. The Patent claims an oral pharmaceutical preparation in the form of a tablet, capsule or pellet containing omeprazole as the active ingredient.  Omeprazole is a compound first synthesised in 1979.  When absorbed in the upper part of the small intestine it inhibits gastric fluid secretions, and is useful in the treatment of gastric and duodenal ulcers.  Astra held Standard Patent No 529,654 under the 1952 Act for this compound ("the compound patent").  This patent has expired and was not in suit in the present litigation.

  3. The discovery of omeprazole and the grant of the compound patent was not itself sufficient to bring about the commercial exploitation of the compound by…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Aktiebolaget Hassle v Alphapharm Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2002] HCA 59
Decision Date

CaseChat Overview and Summary

The High Court of Australia heard an appeal from a decision of the Full Court of the Federal Court concerning the validity of a patent for an oral pharmaceutical preparation. The patent holder, Aktiebolaget Hassle (Astra), appealed a revocation order made by Lehane J and affirmed by the Full Court, which found the invention to be obvious and lacking an inventive step. Alphapharm Pty Ltd was the respondent.

The central legal issue before the High Court was whether the primary judge had erred in law in concluding that the patent was invalid for obviousness. This required the court to consider the principles of patentability, specifically the inventive step requirement, and how they applied to a pharmaceutical formulation arrived at after experimental research. The court also had to determine the relevance of publications discoverable by a routine literature search but not part of the common general knowledge in Australia at the priority date, and whether an invention is obvious if a skilled worker would have considered it "worthwhile to try" its constituent elements.

The High Court's reasoning focused on the primary judge's assessment of the evidence regarding the perceived incompatibility between the enteric coat and the acid-labile omeprazole. The primary judge had noted that no evidence was presented of prior encounters with such a problem, nor of any existing products where this issue had been addressed. Furthermore, evidence indicated that other acid-labile drugs had been successfully enteric coated, and that experts would have initially attempted a direct enteric coating. The court considered the significant experimental work undertaken by Astra, including extensive human trials over several years, and the fact that even an expert tasked with developing the formulation did not arrive at the claimed invention without considerable effort and multiple reports. This extensive research and the lack of prior art suggesting the problem or its solution were key factors in the court's assessment of obviousness.

The High Court allowed the appeal, setting aside the orders of the Full Court of the Federal Court. The matter was remitted to the Full Court for determination of any remaining grounds of appeal, and the revocation order was further stayed. Costs were to be in the discretion of the Full Court.

Orders

Orders of the court

1. Appeal allowed with costs.

2. Set aside orders made by the Full Court of the Federal Court on 9 October 2000.

3. Matter remitted to the Full Court for the determination of any remaining grounds on the respondent's Notice of Contention.

4. Order 2 made by Lehane J on 18 June 1999 dealing with revocation further stayed until further order of the Federal Court.

5. Costs of the whole of the proceedings in the Federal Court to be in the discretion of the Full Court.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

GLEESON CJ, GAUDRON, GUMMOW AND HAYNE JJ HUGH J (dissent)
The evidence of another Astra witness, Dr Cederberg, was concerned with the conduct of trials in humans to see if various formulations proposed in the laboratory actually worked in the body. The Astra formulation team could be sure that the formulation worked only when supplied with these results. Trials were conducted over a period of almost four years.The judgment at trial Before Lehane J, Alphapharm called five expert witnesses, Drs Rowe, Story, Marshall, Thiel and Ashley. The experts called by Astra included Professors Rees and Rhodes, and from its research team Drs Pilbrant and Cederberg, to whose evidence reference has been made. The primary judge noted the evidence of Dr Thiel that an Australian undergraduate at the priority date would have appreciated that an interaction could occur between the acidic enteric coat and the acid labile omeprazole. In a significant passage, his Honour then observed[18]:"If that is so, it may not be unfair to comment that a large scientific team at Astra spent prodigally both time and resources in stumbling towards, and finally upon, what should have been an Australian undergraduate's first thought. But, more importantly, why should it have been thought that the core and the enteric coat were incompatible? No one gave evidence that he had previously, or since, encountered such a problem; there was no evidence of any product manufactured or marketed, before the priority date, in the making of which such a problem had had to be dealt with; there was evidence that other drugs which were both acid labile and alkaline (particularly erythromycin) had been successfully, and directly, enteric coated; each of the Alphapharm witnesses who gave evidence of the approach he would have followed in formulating omeprazole would have first tried a directly enteric coated formulation and (as senior counsel for Astra pointed out) Dr Marshall had no hesitation in applying an enteric coat directly to a core containing a significant quantity of a highly alkaline excipient; and, as the witnesses called by Astra said, there was a perfectly sound scientific explanation: in summary, that interaction should not occur in the absence of any significant quantity of free water."[18](1999) 44 IPR 593 at 625‑626; [1999] AIPC ¶91‑474 at 39,441. To this it may be added, as Lehane J explained, that Dr Marshall had not arrived at the precise formulation claimed in the Patent even after the preparation of six reports on varying instructions from Alphapharm which developed his initial brief to formulate an appropriate dosage form of omeprazole for use by adults[19]. Dr Marshall's evidence was important because, unlike other Alphapharm experts, he was not shown the Patent[20].[19](1999) 44 IPR 593 at 614‑617, 629‑630; [1999] AIPC ¶91‑474 at 39,431-39,435, 39,444-39,445.[20](1999) 44 IPR 593 at 614; [1999] AIPC ¶91‑474 at 39,431. Against that background, at first blush it is surprising that the primary judge held that Alphapharm had made out its case for revocation. It is necessary to trace the steps by which this result was reached.

Ratio Decidendi

Legal Principle Established

Established by: GLEESON CJ, GAUDRON, GUMMOW AND HAYNE JJ,

Full text does not contain this section.